Ep. 87 – Korea’s Biotech Playbook: Orum CEO SJ Lee on Going Global and Creating Novel Therapies
Globalizing quickly and gaining a first-mover advantage are the winning strategies for South Korean biotechs as they look to compete on the world stage, says Orum Therapeutics founder and CEO SJ Lee in conversation with BioCentury Executive Editor Jeff Cranmer on The BioCentury Show.Lee’s company, a leader in degrader-antibody conjugates, provides an example of how to run that playbook. Lee also spoke about where Korea fits in East Asia’s life sciences scene, how Western players can get to know the Korean biopharma industry, and what’s next for Orum’s pipeline. This episode of The BioCentury Show was sponsored by Faron.View full story: https://www.biocentury.com/article/656147#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment02:11 - Korea's Biotech Ecosystem09:57 - Evolution of Korean Biotech16:08 - Orum's Degrader Antibody Conjugates
--------
27:41
Ep. 86 – Macrophages, ASCO & Clever-1: Faron CEO Juho Jalkanen on Bexmarilimab’s Promise
The macrophage field has seen its share of setbacks, but Faron believes bexmarilimab, its humanized mAb that binds to immune checkpoint target Clever-1, has what it takes to get across the goal line at FDA.On a special sponsored edition of The BioCentury Show, Juho Jalkanen, founder and CEO of Faron Pharmaceuticals, explains how the Finnish biotech landed on Clever-1, and why the target might more effectively repolarize macrophages than therapies against other macrophage checkpoints.Jalkanen also discusses the Phase I/II data Faron presented for bexmarilimab in myelodysplastic syndrome at the American Society of Clinical Oncology (ASCO) in Chicago, and what’s next for the immunotherapy. This episode of The BioCentury Show was sponsored by Faron.View full story: https://www.biocentury.com/article/656099#biotech #biopharma #pharma #lifescience #ASCO #RandD #DrugDevelopment
--------
10:22
Ep. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets
Notwithstanding the bad start that the Trump administration got off to on FDA, Tim Opler is optimistic that the agency will serve drug developers well, and sees enough good signals that the direction the agency is headed will not bring the difficult regulatory era that many in the industry feared.Opler, a managing director at Stifel, spoke to Editor in Chief Simone Fishburn on The BioCentury Show about why he’s optimistic about FDA, what he sees ahead for capital markets, competition in China, and three areas of innovation he’s focused on -- aging, women's health and the brain.View full story: https://www.biocentury.com/article/656040#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment #FDA00:00 - Introduction01:30 FDA under Trump 2.008:07 State of Capital Markets13:13 China Competition17:09 Innovation: Aging, Women’s Health & the Brain
--------
32:39
Ep. 84 – Leadership Amid Turmoil: Moonlake CEO Jorge Santos Da Silva
As CEO of a vintage 2021 biotech, Jorge Santos Da Silva has had his leadership mettle tested by a pandemic, rising interest rates, a bear market, and a tumultuous U.S. policy environment — all while building the case for Moonlake’s lead program to become a top therapy for hidradenitis suppurativa and, eventually, a “pipeline-in-a-product.”The key for Santos Da Silva as founder and CEO of Moonlake Immunotherapeutics is to dial down the noise and focus on the key choices in front of you. “Moonlake has always existed in times of turmoil,” Santos Da Silva told Executive Editor Jeff Cranmer on The BioCentury Show, citing the recent M&A drought, high interest rates and political turmoil. “Understanding the situation from a cool perspective, being able to explain that to your people first, and then try to explain that to the Street and place the company in the right moment so that you have all the game in front of you" is his recipe for success as a CEO in biotech. Moonlake’s sonelokimab is expected to enter Phase III testing this year for HS; it's one of the most advanced multispecifics in the clinic for inflammation and immunology diseases.View full story: https://www.biocentury.com/article/655903#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment00:00 - Introduction01:48 - Landscape for HS Therapies09:03 - Market Opportunity19:40 - Next Steps for Moonlake
--------
29:19
Ep. 83 – Europe’s Biotech Moment: Jérôme van Biervliet on Turning Uncertainty into Opportunity
Europe did not ask for this opportunity, says VIB’s Jérôme van Biervliet, but with FDA and the U.S. research funding situation headed into uncertain territory, it needs to use this moment to capitalize on its strengths in research, and address the shortcomings of its business and regulatory systems that have made it hard for biotech to fulfill its potential there. Van Biervliet is managing director of Flanders Institute for Biotechnology (VIB), a key player in the Belgian biotech landscape that has both a research arm and an investment unit. Ahead of BioCentury’s Bio€quity Europe conference in Bruges, which will discuss how Europe can meet the complexity of this moment, he talked to BioCentury Editor in Chief Simone Fishburn on The BioCentury Show about the landscape unfolding in Europe, as well as where he sees innovation headed.View full story: https://www.biocentury.com/article/655818#biotech #biopharma #pharma #LifeScience #ResearchFunding #EuropeanInnovation00:00 - Introduction02:03 - VIB’s Mission07:52 - Europe’s Funding Opportunity17:37 - Belgium’s Biotech Ecosystem25:27 - Nanobodies’ Potential
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
UK